Single agents vs combination chemotherapy in relapsed and refractory peripheral T-cell lymphoma: Results from the comprehensive oncology measures for peripheral T-cell lymphoma treatment (COMPLETE) registry Journal Article

   

Authors:	Stuver, R. N.; Khan, N.; Schwartz, M.; Acosta, M.; Federico, M.; Gisselbrecht, C.; Horwitz, S. M.; Lansigan, F.; Pinter-Brown, L. C.; Pro, B.; Shustov, A. R.; Foss, F. M.; Jain, S.
Article Title:	Single agents vs combination chemotherapy in relapsed and refractory peripheral T-cell lymphoma: Results from the comprehensive oncology measures for peripheral T-cell lymphoma treatment (COMPLETE) registry
Abstract:	Single agents have demonstrated activity in relapsed and refractory (R/R) peripheral T-cell lymphoma (PTCL). Their benefit relative to combination chemotherapy remains undefined. Patients with histologically confirmed PTCL were enrolled in the Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment (COMPLETE) registry. Eligibility criteria included those with R/R disease who had received one prior systemic therapy and were given either a single agent or combination chemotherapy as first retreatment. Treatment results for those with R/R disease who received single agents were compared to those who received combination chemotherapy. The primary endpoint was best response to retreatment. Fifty-seven patients met eligibility criteria. At first retreatment, 46% (26/57) received combination therapy and 54.5% (31/57) received single agents. At median follow up of 2 years, a trend was seen towards increased complete response rate for single agents versus combination therapy (41% vs 19%; P =.02). There was also increased median overall survival (38.9 vs 17.1 months; P =.02) and progression-free survival (11.2 vs 6.7 months; P =.02). More patients receiving single agents received hematopoietic stem-cell transplantation (25.8% vs 7.7%, P =.07). Adverse events of grade 3 or 4 occurred more frequently in those receiving combination therapy, although this was not statistically significant. The data confirm the unmet need for better treatment in R/R PTCL. Despite a small sample, the analysis shows greater response and survival in those treated with single agents as first retreatment in R/R setting, while maintaining the ability to achieve transplantation. Large, randomized trials are needed to identify the best strategy. © 2019 Wiley Periodicals, Inc.
Journal Title:	American Journal of Hematology
Volume:	94
Issue:	6
ISSN:	0361-8609
Publisher:	John Wiley & Sons, Inc.
Date Published:	2019-06-01
Start Page:	641
End Page:	649
Language:	English
DOI:	10.1002/ajh.25463
PUBMED:	30896890
PROVIDER:	scopus
PMCID:	PMC7928240
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85064253078&doi=10.1002%2fajh.25463&partnerID=40&md5=c91e227859b95109754cb60b987ed6cc
Notes:	Article -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/146476